Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXOS110 in Acute Ischaemic Stroke
NCT07520565Phase 3Recruiting
- Sponsor
- Biocells
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human prourokinase in acute ischemic stroke (AIS), sponsored by Biocells. Started Jan 2026; status: recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT07520565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520565.